Elutia Inc
Elutia Inc is a biotechnology company focused on the development and commercialization of innovative pharmaceutical products, primarily in the areas of women's health and urology.
Business. Elutia Inc (ELUT.O) is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm operates within the Healthcare sector, specifically focusing on product sales within the Pharmaceuticals industry. Elutia is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. No specific operating segments or geographic revenue breakdowns are provided in the available data.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Elutia Inc (ELUT.O) is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm operates within the Healthcare sector, specifically focusing on product sales within the Pharmaceuticals industry. Elutia is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. No specific operating segments or geographic revenue breakdowns are provided in the available data.
Elutia's capital structure is highly leveraged, with total liabilities of $85.66 million and total equity of -$50.30 million, indicating a negative net worth. The company's liquidity position is weak, as evidenced by a current ratio of 0.63 and a negative operating cash flow of -$2.64 million. The debt-to-equity ratio of -0.44 further highlights the company's reliance on debt financing, which is atypical for a firm with negative equity.
Profitability metrics are concerning, with a net loss of $17.99 million and an operating loss of $8.48 million. The return on equity (ROE) of 0.3577 is positive but misleading due to the negative equity base. The return on assets (ROA) of -0.5089 indicates that the company is not generating returns from its asset base. Gross profit of $2.84 million is significantly lower than revenue of $6.69 million, suggesting high cost of goods sold or low pricing power.
Elutia's revenue is concentrated in a single business segment, with no disclosed geographic diversification. The company's financial snapshot does not provide segment-specific revenue data, but the lack of diversification increases exposure to market-specific risks. The absence of geographic breakdown suggests a potential concentration risk, particularly if the company's products are regionally dependent.
The company's growth trajectory is uncertain, with no disclosed revenue growth rates or future projections. The negative operating and free cash flows indicate a lack of internal funding for growth initiatives. The capital expenditure of -$15,000 is minimal, suggesting limited investment in long-term growth. Analysts have assigned a mean price target of $5.00, which is significantly higher than the current market price of $1.04, but the lack of strong buy recommendations (0) and the presence of only one buy recommendation suggest cautious sentiment.
Risk factors include high liquidity risk due to negative net cash and a weak balance sheet. The company's dilution risk is currently low, but the negative equity position and high debt levels could necessitate future equity raises, which would dilute existing shareholders. The risk assessment flags a negative net cash position after subtracting total debt, which is a red flag for short-term solvency.
Recent events include the publication of the latest financial data, which shows continued losses and a deteriorating balance sheet. No recent filings or transcripts have been disclosed that provide additional insight into the company's strategic direction or operational performance. The lack of recent positive developments or guidance from management increases uncertainty for investors.
- Elutia is operating with a negative net worth and high debt levels, indicating significant financial distress.
- The company's profitability metrics are weak, with a net loss and negative operating cash flow.
- Revenue concentration in a single segment and lack of geographic diversification increase business risk.
- Analysts have a cautiously optimistic view, with a mean price target of $5.00, but no strong buy recommendations.
- The company's liquidity and solvency risks are high, with a current ratio of 0.63 and negative net cash.
Bull / Bear case
Generated · model-assistedAnalysts project 423.6% upside to a $5.00 target price, signaling strong confidence in future value creation.
Long-term debt reached zero in fiscal 2026, eliminating interest obligations and reducing financial leverage risks significantly.
Free cash flow improved by 64.8% year-over-year in fiscal 2026, demonstrating enhanced operational cash generation capabilities.
Dilution risk is assessed as low, suggesting limited immediate threat to existing shareholder equity value from issuance.
Credit risk is flagged as high, indicating significant concerns regarding the company's ability to meet financial obligations.
Cash conversion ratio of 0.15 is in the bottom quartile, indicating inefficient translation of earnings into cash.
In focus — financials by report
Revenue $3.3M, +16,2% YoY; Operating income +12,0% YoY.
- ▍Revenue $3.3M, +16,2% YoY
- ▍Operating income +12,0% YoY
- ▍Net income +881,3% YoY
- ▍Free cash flow −10,7% YoY
- ▍Net margin 2164.2%
Revenue $3.3M, −9,3% YoY; Operating income +43,2% YoY.
- ▍Revenue $3.3M, −9,3% YoY
- ▍Operating income +43,2% YoY
- ▍Net income −400,8% YoY
- ▍Free cash flow −107,8% YoY
- ▍Net margin -116.4%
Revenue $6.3M, −0,5% YoY; Operating income −16,0% YoY.
- ▍Revenue $6.3M, −0,5% YoY
- ▍Operating income −16,0% YoY
- ▍Net income +65,9% YoY
- ▍Free cash flow +67,9% YoY
- ▍Net margin -153.4%
Revenue $6.0M, −9,9% YoY; Operating income +6,6% YoY.
- ▍Revenue $6.0M, −9,9% YoY
- ▍Operating income +6,6% YoY
- ▍Net income +78,1% YoY
- ▍Free cash flow +80,5% YoY
- ▍Net margin -65.2%
Revenue $2.8M; Operating income -$7.5M.
- ▍Revenue $2.8M
- ▍Operating income -$7.5M
- ▍Net margin -321.8%
Revenue $3.7M; Operating income -$9.2M.
- ▍Revenue $3.7M
- ▍Operating income -$9.2M
- ▍Net margin 35.1%
Revenue $6.3M; Operating income -$8.5M.
- ▍Revenue $6.3M
- ▍Operating income -$8.5M
- ▍Net margin -447.9%
Revenue $6.7M; Operating income -$8.5M.
- ▍Revenue $6.7M
- ▍Operating income -$8.5M
- ▍Net margin -268.8%
Revenue $12.3M, −15,0% YoY; Operating income +12,4% YoY.
- ▍Revenue $12.3M, −15,0% YoY
- ▍Operating income +12,4% YoY
- ▍Net income +198,9% YoY
- ▍Free cash flow +64,8% YoY
- ▍Net margin 434.2%
Revenue $14.5M, −41,5% YoY; Operating income −0,6% YoY.
- ▍Revenue $14.5M, −41,5% YoY
- ▍Operating income −0,6% YoY
- ▍Net income −43,3% YoY
- ▍Free cash flow −12,4% YoY
- ▍Net margin -372.9%
Revenue $24.7M, −49,7% YoY; Operating income +3,8% YoY.
- ▍Revenue $24.7M, −49,7% YoY
- ▍Operating income +3,8% YoY
- ▍Net income −14,5% YoY
- ▍Free cash flow −27,4% YoY
- ▍Net margin -152.2%
Revenue $49.2M, +3,8% YoY; Operating income −53,1% YoY.
- ▍Revenue $49.2M, +3,8% YoY
- ▍Operating income −53,1% YoY
- ▍Net income −32,5% YoY
- ▍Free cash flow −38,3% YoY
- ▍Net margin -66.9%
Valuation TTM
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,54 |
| Revenue | —no estimate | —no estimate | 12,0M USD |
| Operating income | —no estimate | —no estimate | -24,5M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Director, PRESIDENT AND CEO · Restricted Stock Units → Class A Common StockDisposed 22 473exercise · 2026-06-21
- Director, 10% owner · Stock Option (Right to Buy) → Class A Common StockAcquired 159 590 @ $0,96grant · 2026-06-11
- Director · Stock Option (Right to Buy) → Class A Common StockAcquired 106 393 @ $0,96grant · 2026-06-11
- Director · Stock Option (Right to Buy) → Class A Common StockAcquired 106 393 @ $0,96grant · 2026-06-11
- Director · Stock Option (Right to Buy) → Class A Common StockAcquired 106 393 @ $0,96grant · 2026-06-11
- CHIEF FINANCIAL OFFICER · Restricted Stock Units → Class A Common StockDisposed 12 500exercise · 2026-06-10
- CHIEF SCIENTIFIC OFFICER · Restricted Stock Units → Class A Common StockDisposed 12 500exercise · 2026-06-10
- Director, PRESIDENT AND CEO · Restricted Stock Units → Class A Common StockDisposed 27 083exercise · 2026-06-10
- CHIEF SCIENTIFIC OFFICER · Restricted Stock Units → Class A Common StockDisposed 12 500exercise · 2026-03-10
- CHIEF FINANCIAL OFFICER · Restricted Stock Units → Class A Common StockDisposed 12 500exercise · 2026-03-10
- Director, PRESIDENT AND CEO · Restricted Stock Units → Class A Common StockDisposed 27 084exercise · 2026-03-10
- CHIEF FINANCIAL OFFICER · Stock Option (Right to Buy) → Class A Common StockAcquired 368 000 @ $0,69grant · 2026-01-01
- Director, PRESIDENT AND CEO · Stock Option (Right to Buy) → Class A Common StockAcquired 726 000 @ $0,69grant · 2026-01-01
- CHIEF SCIENTIFIC OFFICER · Stock Option (Right to Buy) → Class A Common StockAcquired 368 000 @ $0,69grant · 2026-01-01
- Director · Restricted Stock Units → Class A Common StockDisposed 6 250exercise · 2025-12-10
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Elutia Inc Market data — financials · 2026-05-27
- Elutia Inc Market data — analyst estimates · 2026-05-27
- Elutia Inc Market data — ESG · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
- Director, PRESIDENT AND CEO · Class A Common StockOther 8 064 @ $1,06$9K · 2026-06-21
- Director, PRESIDENT AND CEO · Class A Common StockOther 22 473 · 2026-06-21
- CHIEF FINANCIAL OFFICER · Class A Common StockOther 12 500 · 2026-06-10
- Director, PRESIDENT AND CEO · Class A Common StockOther 27 083 · 2026-06-10
- Director, PRESIDENT AND CEO · Class A Common StockOther 9 718 @ $1,04$10K · 2026-06-10
- CHIEF SCIENTIFIC OFFICER · Class A Common StockOther 4 269 @ $1,04$4K · 2026-06-10
- CHIEF FINANCIAL OFFICER · Class A Common StockOther 4 485 @ $1,04$5K · 2026-06-10
- CHIEF SCIENTIFIC OFFICER · Class A Common StockOther 12 500 · 2026-06-10
- Director, 10% owner · Class A Common StockOther 70 000 · 2026-06-01
- Director, 10% owner · Class A Common StockOther 50 000 · 2026-06-01
- Director, PRESIDENT AND CEO · Class A Common StockOther 11 100 @ $1,09$12K · 2026-03-10
- CHIEF FINANCIAL OFFICER · Class A Common StockOther 5 123 @ $1,09$6K · 2026-03-10
- CHIEF SCIENTIFIC OFFICER · Class A Common StockOther 12 500 · 2026-03-10
- CHIEF SCIENTIFIC OFFICER · Class A Common StockOther 4 613 @ $1,09$5K · 2026-03-10
- Director, PRESIDENT AND CEO · Class A Common StockOther 27 084 · 2026-03-10
- CHIEF FINANCIAL OFFICER · Class A Common StockOther 12 500 · 2026-03-10
- Director · Class A Common StockBought 20 000 @ $1,04$21K · 2026-01-30
- Director, 10% owner · Class A Common StockBought 70 000 @ $1,06$74K · 2026-01-30
- Director · Class A Common StockBought 15 000 @ $1,06$16K · 2026-01-29
- Director · Class A Common StockBought 15 000 @ $1,06$16K · 2026-01-28
- Director, 10% owner · Class A Common StockBought 50 000 @ $0,52$26K · 2025-12-17
- Director · Class A Common StockBought 12 500 @ $0,51$6K · 2025-12-17
- Director · Class A Common StockBought 25 000 @ $0,52$13K · 2025-12-17
- Director, PRESIDENT AND CEO · Class A Common StockBought 3 000 @ $0,51$2K · 2025-12-17
- CHIEF FINANCIAL OFFICER · Class A Common StockBought 60 000 @ $0,53$32K · 2025-12-17
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 174.6%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -57.9%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 146.8%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 72.6%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 159.8%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 38.9%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 12.4%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -97.8%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 198.9%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): -26.5%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 169.4%Derived (calculated)
- Return on equity (FY 2025-12-31): 192.9%Derived (calculated)
- Return on assets (FY 2025-12-31): 85.6%Derived (calculated)
- Current ratio (FY 2025-12-31): 2.22xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 1.25xDerived (calculated)
- Gross profit (YoY) (2025-12-31 vs 2024-12-31): -1.8%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): 186.9%Derived (calculated)
- Cost of revenue (annual): USD 5.7MSEC XBRL filing
- R&D expense (annual): USD 4.16MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES 1SEC XBRL filing
- Pre-tax income (annual): USD -15.86MSEC XBRL filing
- Total assets (annual): USD 62.35MSEC XBRL filing
- Total liabilities (annual): USD 34.68MSEC XBRL filing
- Cash & equivalents (annual): USD 36.35MSEC XBRL filing